Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

preview_player
Показать описание
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.

  1. GRACE - Global Resource for Advancing Cancer Education
  2. GRACE
  3. CancerGRACE
  4. GRACEcast
  5. oncology
  6. lung cancer
Рекомендации по теме
Ceritinib and Other 0:02:00

Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC

Ceritinib and Alectinib 0:05:52

Ceritinib and Alectinib in Relapsed ALK+ NSCLC

ASCEND-1 and ASCEND-2: 0:01:23

ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases

ALK Inhibitors for 0:03:44

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

Ceritinib Alternative Dosing 0:05:21

Ceritinib Alternative Dosing for ALK+ NSCLC

Should a Second 0:04:14

Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?

DEBATE: ALK positive 0:13:28

DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib

FDA Approval: Frontline 0:05:31

FDA Approval: Frontline Ceritinib for ALK+ NSCLC

First and Second 0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

DEBATE: ALK positive 0:11:38

DEBATE: ALK positive NSCLC - Front line therapy - Ceritinib

Results of ASCEND-4 0:05:15

Results of ASCEND-4 trial of ceritinib versus chemotherapy in ALK+ NSCLC patients

Ceritinib in Crizotinib-Resistant 0:07:21

Ceritinib in Crizotinib-Resistant NSCLC

Next-Generation ALK Inhibitors 0:05:53

Next-Generation ALK Inhibitors in Non-Small Cell Lung Cancer

ASCEND-4: Upfront Ceritinib 0:06:37

ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

Keynote Lecture: Targeted 0:33:52

Keynote Lecture: Targeted Therapies in Lung Cancer 2.0 – Advances and Promises

Dr. Chow on 0:01:48

Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the Brain

ASCEND-2 and ASCEND-3 0:01:04

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

Are There Clinically 0:04:44

Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?

Segment 2: Molecular 0:26:57

Segment 2: Molecular Targets in NSCLC

How to maximize 0:03:53

How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer

Alectinib in ALK-Mutated 0:03:59

Alectinib in ALK-Mutated NSCLC

Proactive management of 0:03:48

Proactive management of ceritinib-related gastrointestinal reactions – Video abstract 96471

Upfront Use of 0:06:54

Upfront Use of Next-Generation ALK Inhibitors in NSCLC

Dr. Shaw on 0:02:26

Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer